Thank you for subscribing!
Finfeed Archived May 25, 2021
Initial in vitro studies carried out by Neurotech International Limited (ASX: NTI) in collaboration with the internationally recognised Neurodevelopment in Health and Disease Laboratory at RMIT University to assess the effects of the lead NTI/Dolce strains on key neuro-markets that are used in assessing the onset and progression of Multiple Sclerosis (MS).
Finfeed Archived Mar 17, 2021
Bod Australia (ASX: BDA) is a cannabis centric healthcare company, with well-branded premium, proven and trusted products within two distinct verticals: Medical Cannabis and CBD and Hemp Consumer products.
Finfeed Archived Mar 02, 2021
Neurotech International Limited (ASX: NTI) has expanded its exclusive license with Dolce Cann Global Pty Ltd to now include all neurological disorders, disease or affliction affecting the human brain function, specifically - Autism, Epilepsy, ADHD, Alzheimer’s disease, Huntington’s disease, Multiple Sclerosis, Transverse Myelitis, Inflammatory Brain disease, Fibromyalgia, Chronic Fatigue and Migraine.
Finfeed Archived Jan 21, 2021
Neurotech International Limited (ASX: NTI) has provided a comprehensive overview and update regarding the company’s cannabis strains, development strategy and some of the key near-term objectives expected to be delivered.
Get expert stock analysis direct in your inbox
Catalyst Hunter Archived Dec 16, 2020
Neurotech International Ltd (ASX: NTI) is focused on the clinical applications of unique cannabis strains to treat neurological disorders such as autism and is set to commence human clinical trials early in 2021.
Finfeed Archived Oct 13, 2020
Creso Pharma Limited (ASX: CPH, FRA: 1X8) has once again strengthened its revenue profile with another repeat purchase order from South African-based Pharma Dynamics.
Finfeed Archived May 29, 2020
Cannabis enthusiasts purchase terps and incorporate them into everything from homemade brownies to vape juice. But there’s one industry that’s had surprisingly less of a symbiotic relationship with terpenes than anyone might have expected; namely the cannabis industry.
Next Investors Archived Mar 24, 2020
Creso Pharma Limited (ASX: CPH) is expanding its available product line with the release of a hemp tea in Q3 2020.
Finfeed Archived Feb 06, 2020
Creso Pharma has achieved a key technological milestone, developing its first water-soluble microgranulated hemp plant granules product as an expansion of its cannaQIX® human health product line.
Next Investors Archived Feb 06, 2020
Hot on the heels of major developments in human and animal health, Creso Pharma (ASX:CPH) has achieved another key milestone: a technological breakthrough that will expand its cannaQIX® human health product line,
Next Investors Archived Feb 05, 2020
In January this year, Roots Sustainable Agricultural Technologies Ltd (ASX:ROO) announced it was placing much greater emphasis on pursuing opportunities in the global cannabis sector.
Finfeed Archived Feb 05, 2020
Israeli-based, Roots Sustainable Agricultural Technologies Ltd (ASX:ROO) today announced it has received a further A$30,000 signed order for its RZTO technology.
Finfeed Archived Jan 28, 2020
BPH Energy Limited (ASX:BPH) investee Patagonia Genetics SpA has entered into a joint venture agreement with Israeli based research group Bio-Sciences Pharma Ltd (BSP).
Next Investors Archived Jan 28, 2020
Creso Pharma (ASX:CPH, FRA:1X8) has announced its second major milestone for the year. Today is has informed the market that its flagship cannaQIX® line surpassed the milestone of 100,000 packs sold. The 100,000 pack milestone corresponds to over 2.5 million cannaQIX® lozenges sold since the product’s launch in April 2018.
Creso Pharma Limited (ASX:CPH, FRA:1X8) has informed the market that its flagship cannaQIX® line surpassed the milestone of 100,000 packs sold. The company has already delivered positive news flow throughout January resulting in its share price increasing by more than 70% from about 11 cents at the start of the month to a high of 19 cents.
Finfeed Archived Jan 24, 2020
Cannabis stocks had a challenging year in 2019, but signs are emerging that a change of fortunes is in-store
Next Investors Archived Jan 21, 2020
Momentum has been building over the last couple of months as CresoPharma (ASX:CPH) outlined its strategy for generating substantial growth in 2020.
Finfeed Archived Jan 20, 2020
Shares in Creso Pharma Limited (ASX:CPH, FRA:1X8) soared 20% on Friday after the company released its quarterly report for the three months to 31 December, 2019.
Join Our Mailing List
